Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.52 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.46 |
| ▸ | MAP4K1 | Q92918 | 4/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | PLK4 | O00444 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5097124 | 0.90 | MAPK14 (0.55) | MAPK14MAPK11MAP4K1LCKMAP4K3 | |
| SCHEMBL5097448 | 0.90 | MAPK14 (0.56) | MAPK14MAPK11MAP4K1 | |
| SCHEMBL4015776 | 0.81 | MAPK14 (0.65) | MAPK14MAPK11 | |
| SCHEMBL5100212 | 0.80 | MAPK14 (0.60) | MAPK14MAPK11MAP4K1LCKMAP4K3 | |
| SCHEMBL3969566 | 0.78 | MAPK14 (0.62) | MAPK14MAPK11PLK4 | |
| SCHEMBL5100907 | 0.77 | MAPK14 (0.56) | MAPK14MAPK11 | |
| SCHEMBL5097310 | 0.76 | MAPK14 (0.59) | MAPK14MAPK11MAP4K1 | |
| SCHEMBL5106939 | 0.75 | MAPK14 (0.61) | MAPK14MAPK11 | |
| SCHEMBL5100172 | 0.75 | MAPK14 (0.61) | MAPK14MAPK11 | |
| SCHEMBL5100009 | 0.75 | MAPK14 (0.61) | MAPK14MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7452880-B2 | Substituted pyrazolo [3,4-d] pyrimidines and methods of using the same | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-18 | — | — | US | claimed |
| EP-1720878-A1 | HETEROARYL-FUSED PYRAZOLO DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-11-15 | — | — | EP | claimed |
| WO-2005085248-A1 | HETEROARYL-FUSED PYRAZOLO DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2005-09-15 | — | — | WO | claimed |
| US-7452880-B2 | Substituted pyrazolo [3,4-d] pyrimidines and methods of using the same | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-18 | — | — | US | disclosed |
| US-7452880-B2 | Substituted pyrazolo [3,4-d] pyrimidines and methods of using the same | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-18 | — | — | US | disclosed |
| US-7452880-B2 | Substituted pyrazolo [3,4-d] pyrimidines and methods of using the same | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-18 | — | — | US | disclosed |
| US-20050203091-A1 | Heteroaryl-fused pyrazolo derivatives and methods for using the same | ROCHE PALO ALTO LLC | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203091-A1 | Heteroaryl-fused pyrazolo derivatives and methods for using the same | MAP3K1, MAP3K21, MAP3K2 | MAPK14 48/4885MAPK11 58/4885MAP4K1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.